ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis

This article originally appeared here.
Share this content:
ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis
ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis

MONDAY, Sept. 11, 2017 (HealthDay News) -- Romosozumab treatment followed by alendronate is linked to reduced risk of fractures versus alendronate alone for postmenopausal women with osteoporosis, according to a study published online Sept. 11 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society for Bone and Mineral Research, held from Sept. 8 to 11 in Denver.

Kenneth G. Saag, M.D., from the University of Alabama in Birmingham, and colleagues randomized 4,093 postmenopausal women with osteoporosis and a fragility fracture to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months, followed by open-label alendronate in both groups.

The researchers found that the risk of new vertebral fracture was 48 percent lower in the romosozumab-to-alendronate versus the alendronate-to-alendronate group (6.2 versus 11.9 percent; P < 0.001), over a period of 24 months. Clinical fractures occurred in 9.7 and 13.0 percent of patients in the romosozumab-to-alendronate and the alendronate-to-alendronate groups, respectively (27 percent lower risk with romosozumab; P < 0.001). The risk of nonvertebral fractures was 19 percent lower in the romosozumab-to-alendronate versus the alendronate-to-alendronate group (8.7 versus 10.6 percent; P = 0.04) and the risk of hip fracture was 38 percent lower (2.0 versus 3.2 percent; P = 0.02).

"In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone," the authors write.

The study was partially funded by Amgen, the manufacturer of romosozumab.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Out-of-Pocket Expenditures Down With ACA Implementation

Out-of-Pocket Expenditures Down With ACA Implementation

Reduced out-of-pocket costs seen especially for lower-income groups; mean premium costs up overall

Gynecologic Complications Up With Hysteroscopic Sterilization

Gynecologic Complications Up With Hysteroscopic Sterilization

But lower risk of surgical and medical complications versus laparoscopic sterilization

Prevalence of Cigarette Smoking 15.5 Percent in 2016

Prevalence of Cigarette Smoking 15.5 Percent in 2016

Increase in percentage of ever smokers who quit during 2005 to 2016, from 50.8 to 59 percent

is free, fast, and customized just for you!

Already a member?

Sign In Now »